The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection

被引：14

作者：

Marsavela, Gabriela ^{[1
]}

Johansson, Peter A. ^{[2
]}

Pereira, Michelle R. ^{[1
]}

McEvoy, Ashleigh C. ^{[1
]}

Reid, Anna L. ^{[1
]}

Robinson, Cleo ^{[3
,4
]}

Warburton, Lydia ^{[1
,5
]}

Khattak, Muhammad A. ^{[1
,6
,7
]}

Meniawy, Tarek M. ^{[1
,5
,6
]}

Amanuel, Benhur ^{[1
,3
,6
]}

Millward, Michael ^{[5
,6
]}

Hayward, Nicholas K. ^{[2
]}

Ziman, Melanie R. ^{[1
,4
]}

Gray, Elin S. ^{[1
]}

Calapre, Leslie ^{[1
]}

机构：

[1] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA 6027, Australia

[2] QIMR Berghofer Med Res Inst, Brisbane, Qld 4006, Australia

[3] QEII Med Ctr, PathWest Lab Med, Anat Pathol, Nedlands, WA 6009, Australia

[4] Univ Western Australia, Sch Biomed Sci, Crawley, WA 6009, Australia

[5] Sir Charles Gairdner Hosp, Dept Med Oncol, Nedlands, WA 6010, Australia

[6] Univ Western Australia, Sch Med, Crawley, WA 6009, Australia

[7] Fiona Stanley Hosp, Dept Med Oncol, Murdoch, WA 6150, Australia

来源：

CANCERS | 2020年 / 12卷 / 12期

基金：

澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;

关键词：

circulating tumour DNA (ctDNA); melanoma; BRAF; response; targeted therapy; immunotherapy; neoantigen load; tumour mutational burden; MUTATION ANALYSIS; LIQUID BIOPSIES; IPILIMUMAB; BLOCKADE; PEMBROLIZUMAB; NIVOLUMAB; CELLS;

D O I：

10.3390/cancers12123793

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Circulating tumour DNA (ctDNA) has been shown to be an informative biomarker in melanoma. Here we analysed plasma ctDNA in a real-world metastatic melanoma cohort. We found the kinetics of ctDNA decline are delayed in patients treated with immunotherapy compared to those receiving MAPK inhibitors. Nonetheless, decreasing ctDNA levels within 12 weeks of immunotherapy or BRAF/MEK inhibitors was strongly concordant with treatment response and significantly associated with longer progression-free survival (PFS). Furthermore, exploratory analysis of nine patients commencing anti-PD-1 therapy showed a trend of high tumour mutational burden and neoepitope load in responders compared to non-responders. The results support the use of ctDNA as a dynamic biomarker for assessment of response in melanoma patients. In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA) to inform therapeutic outcomes in metastatic melanoma patients receiving systemic therapies. We analysed 142 plasma samples from metastatic melanoma patients prior to commencement of systemic therapy: 70 were treated with BRAF/MEK inhibitors and 72 with immunotherapies. Patient-specific droplet digital polymerase chain reaction assays were designed for ctDNA detection. Plasma ctDNA was detected in 56% of patients prior to first-line anti-PD1 and/or anti-CTLA-4 treatment. The detection rate in the immunotherapy cohort was comparably lower than those with BRAF inhibitors (76%, p = 0.0149). Decreasing ctDNA levels within 12 weeks of treatment was strongly concordant with treatment response (Cohen's k = 0.798, p < 0.001) and predictive of longer progression free survival. Notably, a slower kinetic of ctDNA decline was observed in patients treated with immunotherapy compared to those on BRAF/MEK inhibitors. Whole exome sequencing of ctDNA was also conducted in 9 patients commencing anti-PD-1 therapy to derive tumour mutational burden (TMB) and neoepitope load measurements. The results showed a trend of high TMB and neoepitope load in responders compared to non-responders. Overall, our data suggest that changes in ctDNA can serve as an early indicator of outcomes in metastatic melanoma patients treated with systemic therapies and therefore may serve as a tool to guide treatment decisions.

引用

页码：1 / 13

页数：13

共 41 条

[1] Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy [J].

Alix-Panabieres, Catherine ;

Pantel, Klaus .

CANCER DISCOVERY, 2016, 6 (05) :479-491

[2] Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma [J].

Ascierto, Paolo A. ;

Minor, David ;

Ribas, Antoni ;

Lebbe, Celeste ;

O'Hagan, Anne ;

Arya, Niki ;

Guckert, Mary ;

Schadendorf, Dirk ;

Kefford, Richard F. ;

Grob, Jean-Jacques ;

Hamid, Omid ;

Amaravadi, Ravi ;

Simeone, Ester ;

Wilhelm, Tabea ;

Kim, Kevin B. ;

Long, Georgina V. ;

Martin, Anne-Marie ;

Mazumdar, Jolly ;

Goodman, Vicki L. ;

Trefzer, Uwe .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3205-+

[3] Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies [J].

Bettegowda, Chetan ;

Sausen, Mark ;

Leary, Rebecca J. ;

Kinde, Isaac ;

Wang, Yuxuan ;

Agrawal, Nishant ;

Bartlett, Bjarne R. ;

Wang, Hao ;

Luber, Brandon ;

Alani, Rhoda M. ;

Antonarakis, Emmanuel S. ;

Azad, Nilofer S. ;

Bardelli, Alberto ;

Brem, Henry ;

Cameron, John L. ;

Lee, Clarence C. ;

Fecher, Leslie A. ;

Gallia, Gary L. ;

Gibbs, Peter ;

Le, Dung ;

Giuntoli, Robert L. ;

Goggins, Michael ;

Hogarty, Michael D. ;

Holdhoff, Matthias ;

Hong, Seung-Mo ;

Jiao, Yuchen ;

Juhl, Hartmut H. ;

Kim, Jenny J. ;

Siravegna, Giulia ;

Laheru, Daniel A. ;

Lauricella, Calogero ;

Lim, Michael ;

Lipson, Evan J. ;

Marie, Suely Kazue Nagahashi ;

Netto, George J. ;

Oliner, Kelly S. ;

Olivi, Alessandro ;

Olsson, Louise ;

Riggins, Gregory J. ;

Sartore-Bianchi, Andrea ;

Schmidt, Kerstin ;

Shih, Ie-Ming ;

Oba-Shinjo, Sueli Mieko ;

Siena, Salvatore ;

Theodorescu, Dan ;

Tie, Jeanne ;

Harkins, Timothy T. ;

Veronese, Silvio ;

Wang, Tian-Li ;

Weingart, Jon D. .

SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (224)

[4]

Borcoman Edith, 2018, Am Soc Clin Oncol Educ Book, V38, P169, DOI 10.1200/EDBK_200643

[5] Implementing TMB measurement in clinical practice: considerations on assay requirements [J].

Buettner, Reinhard ;

Longshore, John W. ;

Lopez-Rios, Fernando ;

Merkelbach-Bruse, Sabine ;

Normanno, Nicola ;

Rouleau, Etienne ;

Penault-Llorca, Frederique .

ESMO OPEN, 2019, 4 (01)

[6] Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study [J].

Cabel, L. ;

Riva, F. ;

Servois, V. ;

Livartowski, A. ;

Daniel, C. ;

Rampanou, A. ;

Lantz, O. ;

Romano, E. ;

Milder, M. ;

Buecher, B. ;

Piperno-Neumann, S. ;

Bernard, V. ;

Baulande, S. ;

Bieche, I. ;

Pierga, J. Y. ;

Proudhon, C. ;

Bidard, F. -C. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1996-2001

[7] Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma [J].

Calapre, Leslie ;

Giardina, Tindaro ;

Robinson, Cleo ;

Reid, Anna L. ;

Al-Ogaili, Zeyad ;

Pereira, Michelle R. ;

McEvoy, Ashleigh C. ;

Warburton, Lydia ;

Hayward, Nicholas K. ;

Khattak, Muhammad A. ;

Meniawy, Tarek M. ;

Millward, Michael ;

Amanuel, Benhur ;

Ziman, Melanie ;

Gray, Elin S. .

MOLECULAR ONCOLOGY, 2019, 13 (02) :171-184

[8] Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma [J].

Calapre, Leslie ;

Warburton, Lydia ;

Millward, Michael ;

Ziman, Mel ;

Gray, Elin S. .

CANCER LETTERS, 2017, 404 :62-69

[9]

Callahan MK, 2016, CANCER TREAT RES, V167, P231, DOI 10.1007/978-3-319-22539-5_9

[10] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

← 1 2 3 4 5 →